1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grants2025 Research Grant Applications is sponsored by National Bleeding Disorders Foundation (NBDF). Supports investigators at various career stages dedicated to advancing bleeding disorders research and clinical care.
Get alerted about grants like this
Save a search for “National Bleeding Disorders Foundation (NBDF)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NBDF Opens 2025 Research Grant Applications | NBDF NBDF does not endorse products or manufacturers. The National Hemophilia Foundation Has a New Name The Red Thread: 75th Anniversary Celebration Physical Therapy Working Group Social Work Working Group LEE Research Advisory Council What is a Bleeding Disorder?
Women and Bleeding Disorders Other Factor Deficiencies Inherited Platelet Disorders Comprehensive Medical Care Treatment Guidelines (MASAC) Hemophilia Treatment Centers Choosing an Insurance Plan Bleeding Disorders Conference Gene and Innovative Therapies Blood & Blood Product Safety Patient Out-of-Pocket Expenses Voices for Policy Change!
6 Steps for Grassroots Advocacy Collaborating on Coverage Quality of Care Guidelines Quality Improvement & Cost Management Presented at Our Conference Clinical Trial Essentials coreHem Mental Health Tool Judith Graham Pool Postdoctoral Research Fellowship NBDF-Sanofi Career Development Award Nursing Excellence Fellowship Physical Therapy Excellence Fellowship Social Work Excellence Fellowship Community Voices in Research How & Why Should I Participate?
Frequently Asked Questions Bleeding Disorders Research Collaborative What is the Bleeding Disorders Research Collaborative?
The BDRC Structure and Research Priorities Lived Experience Experts (LEEs) Leading the Way Snapshots of VWD Guidelines NBDF-Takeda Clinical Fellowship Program NBDF’s Collaborative Learning Exchange Online Education for Providers Live & Online Learning (Partners Program) Rare Coagulation Disorders Resource Room Other Interdisciplinary Healthcare Providers The Neil Frick Resource Center Hemophilia Treatment Centers Community Voices in Research Patient Assistance Programs Donate Securities or Cryptocurrency Become a Corporate Partner Bleeding Disorders Awareness Month Participate in Research/CVR Create Your Own Fundraiser NBDF’s Established Initiatives & Impact > NBDF Opens 2025 Research Grant Applications National Bleeding Disorders Foundation NBDF Opens 2025 Research Grant Applications Annual Funding Program Supports Investigators Across Career Stages "These research grants represent a critical investment in the future of bleeding disorders treatment," said Halli Benasutti , PhD, Director of Research Grants at NBDF .
"Each year, we see remarkable proposals from scientists and healthcare providers who are passionate about improving patient care. By funding research across different career stages and disciplines, we're accelerating the path from scientific discovery to better outcomes for our community."
The Judith Graham Pool (JGP) Postdoctoral Research Fellowships , offering $52,000 annually for two years to support postdoctoral researchers investigating biochemical, genetic, or hematological aspects of bleeding disorders. The Excellence Awards , granting $15,000 for 12–18-month projects led by Nursing, Physical Therapy, and Social Work providers in clinical treatment center settings.
These opportunities support a range of research from basic science to clinical projects and innovative technologies, reinforcing NBDF's comprehensive approach to advancing the field. The foundation welcomes applications from qualified researchers and healthcare providers nationwide.
"Each year, these grant programs create vital opportunities for researchers to pursue promising investigations that can transform our understanding and treatment of bleeding disorders," said Maria E. Santaella , PhD(c), MSN, RN-BC, CPHON, Vice President of Research at NBDF.
"From supporting early-career scientists to funding experienced investigators and clinical practitioners, we're investing in research that directly impacts patient care. The discoveries made by our grant recipients continue to drive meaningful advances in treatment options and quality of life for individuals with bleeding disorders." Interested investigators are encouraged to contact hbenasutti@bleeding.
org . Complete program information can be found at www. bleeding.
org . To Submit Letter of Intent About The National Bleeding Disorders Foundation The National Bleeding Disorders Foundation (NBDF) is dedicated to finding cures for inheritable blood and bleeding disorders and addressing and preventing these disorders' complications through research, education, and advocacy, enabling people and families to thrive.
Today, NBDF serves people across the United States with all bleeding disorders, including hemophilia , von Willebrand disease , rare factor deficiencies , and platelet disorders . The foundation also supports a network of 52 chapters across the country. NBDF has changed its name from the National Hemophilia Foundation to the National Bleeding Disorders Foundation , and its domain name has been changed from hemophilia.
org to bleeding. org . For questions, don't hesitate to get in touch with Kyla Clark, Director of Public Relations, Marketing and Communications at kclark@bleeding.
org . Government Relations Update - March 2026 Takeda Updates HEMOFIL® M and RECOMBINATE Availability for Hemophilia A Patients 2026 Educational Scholarships List is Up! HEMGENIX Gene Therapy Facing Temporary Global Supply Disruption NBDF does not endorse products or manufacturers.
Based on current listing details, eligibility includes: Investigators at various career stages in bleeding disorders research. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.